research use only

Myristic Acid Src inhibitor

Name: Myristic Acid
Brand: Selleck Chemicals
SKU: S5617
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S5617

Myristic acid (Tetradecanoic acid) is a fatty acid that occurs naturally in some foods. Myristic acid inhibits the phosphorylation of poly E4Y by Src with an Ki of 35 μM.

Chemical Structure

Molecular Weight: 228.37

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S561701 DMSO]100 mg/mL]false]Water]Insoluble]false]]]false Purity: 98%

Related Targets	EGFR VEGFR JAK PDGFR FGFR FLT3 HER2 Bcr-Abl HIF BTK ALK Syk FAK VDA
Related Products	Saracatinib (AZD0530) PP2 (AGL 1879) SU6656 PP1 WH-4-023 Src Inhibitor 1 RK 24466 eCF506 Tolimidone (MLR-1023) UM-164 p130 Cas Antibody [P2F10] KX1-004 Phospho-Src Family (Tyr416) Antibody [H4N15] 7-Hydroxy-4-chromone Hck Antibody [J1M6] Lyn Antibody [D23D4] DGY-06-116 CSK Antibody [M12C3] A 419259 Src Antibody [H13N7] Phospho-Src (Tyr529) Antibody [D13P6] 1-Naphthyl PP1 hydrochloride Lyn Antibody [F9H10] TL02-59 AMG-47a Phospho-Lyn (Tyr507) Antibody [E9D13] Fyn Antibody [K9B3] AD1058 Lck Inhibitor 1-Naphthyl PP1(1-NA-PP1)

Chemical Information, Storage & Stability

Molecular Weight	228.37	Formula	C₁₄H₂₈O₂	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	544-63-8	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Tetradecanoic acid			Smiles	CCCCCCCCCCCCCC(=O)O

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (437.88 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.750mg/ml (16.42mM)	Taking the 1 mL working solution as an example, add 50 μL of 75 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	Src ^[1] (Cell-free assay) 35 μM(Ki)
References	[1] https://pubmed.ncbi.nlm.nih.gov/10424353/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03314831	Completed	Sepsis Syndrome\|Systemic Inflammatory Response Syndrome	Charles University Czech Republic	October 24 2017	--
NCT02502578	Completed	Idiopathic Triglyceride Deposit Cardiomyovasculopathy	Osaka University	September 2015	Phase 1\|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):